01/29/2026
We’re excited to share that PranaX has closed an oversubscribed $17M Series A round, led by family offices and strategic investors with deep expertise in biotechnology and regenerative medicine. The funding supports PranaX’s next phase of growth as the exosome sector continues to gain momentum.
Read more here: https://na2.hubs.ly/H03ldn20